Biology Reference
In-Depth Information
Hamzah, J., Jugold, M., Kiessling, F., Rigby, P., Manzur, M., Marti, H.H., Rabie, T., Kaden,
S., Grone, H.J., Hammerling, G.J., Arnold, B., Ganss, R., 2008. Vascular normalization in
Rgs5-deficient tumours promotes immune destruction. Nature 453, 410-414.
Han, S., Arnold, S.A., Sithu, S.D., Mahoney, E.T., Geralds, J.T., Tran, P., Benton, R.L., Mad-
die, M.A., D'Souza, S.E., Whittemore, S.R., Hagg, T., 2010. Rescuing vasculature with
intravenous angiopoietin-1 and alpha v beta 3 integrin peptide is protective after spinal
cord injury. Brain 133, 1026-1042.
Hanada, T., Nakagawa, M., Emoto, A., Nomura, T., Nasu, N., Nomura, Y., 2000. Prognostic
value of tumor-associated macrophage count in human bladder cancer. Int. J. Urol. 7,
263-269.
Hanahan, D., Weinberg, R.A., 2000. The hallmarks of cancer. Cell 100, 57-70.
Harris, J.A., Jain, S., Ren, Q., Zarineh, A., Liu, C., Ibrahim, S., 2012. CD163 versus CD68
in tumor associated macrophages of classical Hodgkin lymphoma. Diagn. Pathol. 7, 12.
Hedlund, E.M., Hosaka, K., Zhong, Z., Cao, R., Cao, Y., 2009. Malignant cell-derived PlGF
promotes normalization and remodeling of the tumor vasculature. Proc. Natl. Acad. Sci.
U.S.A. 106, 17505-17510.
Hiratsuka, S., Minowa, O., Kuno, J., Noda, T., Shibuya, M., 1998. Flt-1 lacking the tyrosine
kinase domain is sufficient for normal development and angiogenesis in mice. Proc. Natl.
Acad. Sci. U.S.A. 95, 9349-9354.
Hiratsuka, S., Watanabe, A., Aburatani, H., Maru, Y., 2006. Tumour-mediated upregulation of
chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat.
Cell Biol. 8, 1369-1375.
Hiratsuka, S., Watanabe, A., Sakurai, Y., kashi-Takamura, S., Ishibashi, S., Miyake, K., Shibuya,
M., Akira, S., Aburatani, H., Maru,Y., 2008. The S100A8-serum amyloid A3-TLR4 para-
crine cascade establishes a pre-metastatic phase. Nat. Cell Biol. 10, 1349-1355.
Huang, Y., Snuderl, M., Jain, R.K., 2011. Polarization of tumor-associated macrophages: a
novel strategy for vascular normalization and antitumor immunity. Cancer Cell 19, 1-2.
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin,
J., Baron, A., Griffing, S., Holmgren, E., Ferrara, N., Fyfe, G., Rogers, B., Ross, R., Kab-
binavar, F., 2004. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for meta-
static colorectal cancer. N. Engl. J. Med. 350, 2335-2342.
Inaba, T., Sano, H., Kawahito,Y., Hla, T., Akita, K., Toda, M.,Yamashina, I., Inoue, M., Nakada,
H., 2003. Induction of cyclooxygenase-2 in monocyte/macrophage by mucins secreted
from colon cancer cells. Proc. Natl. Acad. Sci. U.S.A. 100, 2736-2741.
Ishii, M., Wen, H., Corsa, C.A., Liu, T., Coelho, A.L., Allen, R.M., Carson, W.F., Cavassani,
K.A., Li, X., Lukacs, N.W., Hogaboam, C.M., Dou, Y., Kunkel, S.L., 2009. Epigenetic
regulation of the alternatively activated macrophage phenotype. Blood 114, 3244-3254.
Jain, R.K., 2001. Normalizing tumor vasculature with anti-angiogenic therapy: a new para-
digm for combination therapy. Nat. Med. 7, 987-989.
Jain, R.K., 2005. Normalization of tumor vasculature: an emerging concept in antiangio-
genic therapy. Science 307, 58-62.
Johansen, J.S., Jensen, B.V., Roslind, A., Nielsen, D., Price, P.A., 2006. Serum YKL-40, a
new prognostic biomarker in cancer patients? Cancer Epidemiol. Biomarkers Prev. 15,
194-202.
Joyce, J.A., 2005. Therapeutic targeting of the tumor microenvironment. Cancer Cell 7,
513-520.
Jung, C.H., Ro, S.H., Cao, J., Otto, N.M., Kim, D.H., 2010. mTOR regulation of autophagy.
FEBS Lett. 584, 1287-1295.
Kalin, T.V., Ustiyan, V., Kalinichenko, V.V., 2011. Multiple faces of FoxM1 transcription fac-
tor: lessons from transgenic mouse models. Cell Cycle 10, 396-405.
Kashiwagi, S., Tsukada, K., Xu, L., Miyazaki, J., Kozin, S.V., Tyrrell, J.A., Sessa, W.C., Ger-
weck, L.E., Jain, R.K., Fukumura, D., 2008. Perivascular nitric oxide gradients normalize
tumor vasculature. Nat. Med. 14, 255-257.
Search WWH ::
Custom Search